NASDAQ:CDXS - Codexis Stock Price, Price Target & More

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company earned $14.04 million during the quarter, compared to analysts' expectations of $13.50 million. Codexis had a negative return on equity of 87.65% and a negative net margin of 36.06%. View Codexis' Earnings History.

3 brokers have issued 1-year price targets for Codexis' stock. Their predictions range from $11.00 to $16.00. On average, they anticipate Codexis' share price to reach $13.00 in the next twelve months. View Analyst Ratings for Codexis.

Some companies that are related to Codexis include Sensient Technologies (SXT), Green Plains (GPRE), Westlake Chemical Partners (WLKP), Renewable Energy Group (REGI), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Amyris (AMRS), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), China Insonline (WAYS), Aemetis (AMTX), CTD (CTDH) and OriginClear (OCLN).

News articles about CDXS stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Codexis earned a news sentiment score of 0.20 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Codexis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (4.33%), Prescott Group Capital Management L.L.C. (2.44%), Wells Fargo & Company MN (2.22%), Lord Abbett & CO. LLC (1.29%), First Light Asset Management LLC (1.19%) and Cortina Asset Management LLC (0.97%). Company insiders that own Codexis stock include Bernard J Kelley, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Cortina Asset Management LLC, First Light Asset Management LLC and Blair William & Co. IL. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Insider Buying and Selling for Codexis.

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Baillie Gifford & Co., Bradley Foster & Sargent Inc. CT, Wells Fargo & Company MN, Spark Investment Management LLC, EAM Global Investors LLC, CIBC World Markets Inc. and Millennium Management LLC. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $15.45.

Codexis has a market capitalization of $814.58 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]dexis.com.